Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $298,080 - $391,230
40,500 Added 142.11%
69,000 $511 Million
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $127,925 - $190,750
17,500 Added 159.09%
28,500 $228 Million
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $89,430 - $151,470
11,000 New
11,000 $128 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $415M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Crawford Fund Management, LLC Portfolio

Follow Crawford Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crawford Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crawford Fund Management, LLC with notifications on news.